Disease · MONDO_0100135
Comparisons in its trials13
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 13 of 13
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Soticlestat vs Placebo: deaths from any cause | 1 of 73 | 0 of 71 | 144 | NCT04940624 | Trial comparisons |
| Soticlestat vs Placebo: serious adverse events | 7 of 73 | 10 of 71 | 144 | NCT04940624 | Trial comparisons |
| TAK-935 vs Placebo: deaths from any cause | 0 of 71 | 0 of 70 | 141 | NCT03650452 | Trial comparisons |
| TAK-935 vs Placebo: serious adverse events | 11 of 71 | 13 of 70 | 141 | NCT03650452 | Trial comparisons |
| Cohort 2: ZX008 0.5 mg/kg/Day vs Cohort 2: Matching Placebo: deaths from any cause | 0 of 43 | 0 of 44 | 87 | NCT02926898 | Trial comparisons |
| Cohort 2: ZX008 0.5 mg/kg/Day vs Cohort 2: Matching Placebo: serious adverse events | 6 of 43 | 7 of 44 | 87 | NCT02926898 | Trial comparisons |
| Ataluren vs Placebo: deaths from any cause | 0 of 15 | 0 of 14 | 29 | NCT02758626 | Trial comparisons |
| Ataluren vs Placebo: serious adverse events | 7 of 15 | 1 of 14 | 29 | NCT02758626 | Trial comparisons |
| Core Study: Lorcaserin vs Core Study: Placebo: Core Study: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 9 of 11 | 7 of 10 | 21 | NCT04572243 | Trial comparisons |
| Tuberous Sclerosis Complex vs Dravet Syndrome: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 2 of 2 | 1 of 1 | 3 | NCT04485104 | Trial comparisons |
| Tuberous Sclerosis Complex vs Dravet Syndrome: deaths from any cause | 0 of 2 | 0 of 1 | 3 | NCT04485104 | Trial comparisons |
| Tuberous Sclerosis Complex vs Dravet Syndrome: Number of Participants With Emergence of New Types of Seizures | 1 of 2 | 0 of 1 | 3 | NCT04485104 | Trial comparisons |
| Tuberous Sclerosis Complex vs Dravet Syndrome: serious adverse events | 2 of 2 | 0 of 1 | 3 | NCT04485104 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0100135/comparisons